[Mechanisms of Resistance in Antihormone Therapies of Advanced Prostate Cancer].

With the development of Abiraterone and Enzalutamide new treatment option have become available in addition to Docetaxel for first-line treatment of castration resistant prostate cancer. However, resistance and ultimately failure occurs inevitably with all available treatment options.

Moreover, cross-resistance leads to considerably reduced efficacy in second-line treatment. Preclinical data suggest discriminative mechanisms of resistance development for Abiraterone and Enzalutamide. Clinical confirmation of these putative mechanisms for treatment failure might facilitate recommendations for future sequencing of these drugs.

Aktuelle Urologie. 2016 Jan 27 [Epub ahead of print]

P Thelen, J Gschwend, J-M Wolff, K Miller

Urologische Klinik und Poliklinik, Universitätsmedizin Göttingen. , Urologische Klinik und Poliklinik der Technischen Universität München. , Paracelsus-Klinik Golzheim Düsseldorf. , Klinik für Urologie, Charité - Universitätsmedizin Berlin.

PubMed